VA Study to Test Values-Based Intervention for Veterans in Buprenorphine Treatment
This study represents a significant advancement in addressing the psychological and social challenges faced by Veterans undergoing buprenorphine treatment for opioid use disorder. If successful, it could lead to the development of integrated treatment protocols that enhance overall therapeutic outcomes, which is critical for improving patient care in this demographic.
Phase III
Substance Use Disorder / Opioid Use Disorder
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Strategic implication
This study represents a significant advancement in addressing the psychological and social challenges faced by Veterans undergoing buprenorphine treatment for opioid use disorder. If successful, it could lead to the development of integrated treatment protocols that enhance overall therapeutic outcomes, which is critical for improving patient care in this demographic.
Why it matters
This study represents a significant advancement in addressing the psychological and social challenges faced by Veterans undergoing buprenorphine treatment for opioid use disorder. If successful, it could lead to the development of integrated treatment protocols that enhance overall therapeutic outcomes, which is critical for improving patient care in this demographic.
What changed
Trial Update
Analysis
A new study will evaluate a brief, values-based intervention aimed at improving interpersonal functioning in Veterans undergoing early buprenorphine treatment.
This study represents a significant advancement in addressing the psychological and social challenges faced by Veterans undergoing buprenorphine treatment for opioid use disorder. If successful, it could lead to the development of integrated treatment protocols that enhance overall therapeutic outcomes, which is critical for improving patient care in this demographic.
Monitor results from the pilot randomized controlled trial and feedback from participants regarding treatment effectiveness.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.